NCT01805934View on ClinicalTrials.gov

Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
Rescue Therapy for Helicobacter Pylori
Interventions
DRUG

RBLF

The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).

DRUG

RA

The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).

Trial Locations (1)

Unknown

Shanghai Renji Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT01805934 - Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection | Biotech Hunter | Biotech Hunter